Serono spinout grabs a $31M round for a pair of proof-of-concept Parkinson’s trials
Nearly 5 years ago, Prexton Therapeutics was the first new biotech to be spun out of the wreckage left behind after Merck KGaA decided to shutter its big Serono operations in Geneva and retrench back in Darmstadt. Today, it’s taking what it learned in a Phase I study of a new Parkinson’s drug and applying it in a pair of mid-stage studies that will put its theories on a new pathway to the test, fueled by a $31 million Series B.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.